Pharmacokinetics of Long-acting Injectable Neuroleptic Drugs: Clinical Implications

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1989 Jan 1

PMID 2570430

Citations 5

Authors

S R Marder

J W Hubbard

T Van Putten

K K Midha

Affiliations

Soon will be listed here.

Abstract

The authors review the literature regarding the pharmacokinetics of long-acting injectable neuroleptic drugs (LINS). There are important differences between LINS and oral neuroleptics that affect their pharmacokinetics. By avoiding first pass metabolism in gut and liver, LINS result in lower circulating concentrations of metabolites than are found after oral administration. In addition, LINS take more time to reach a stable steady state than their oral counterparts. The clinical significance of these pharmacokinetic properties is discussed. The authors recommend that when patients are being changed from oral neuroleptics to LINS, that this conversion be done gradually over several months.

Citing Articles

Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis-A Retrospective Mirror-Image Study.

Chan C, Verma S, Subramaniam M, Abdin E, Tay J Int J Environ Res Public Health. 2023; 20(4).

PMID: 36834095 PMC: 9961511. DOI: 10.3390/ijerph20043403.

The Black Book of Psychotropic Dosing and Monitoring.

Schatzberg A, Charles D Psychopharmacol Bull. 2018; 48(1):64-153.

PMID: 29382960 PMC: 5765435.

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Brissos S, Ruiz Veguilla M, Taylor D, Balanza-Martinez V Ther Adv Psychopharmacol. 2014; 4(5):198-219.

PMID: 25360245 PMC: 4212490. DOI: 10.1177/2045125314540297.

Pharmacokinetic optimisation of the treatment of psychosis.

Balant L, Andreoli A Clin Pharmacokinet. 1993; 25(3):217-36.

PMID: 7900948 DOI: 10.2165/00003088-199325030-00005.

Structural changes by sulfoxidation of phenothiazine drugs.

Dahl S, Kollman P, Rao S, Singh U J Comput Aided Mol Des. 1992; 6(3):207-22.

PMID: 1355521 DOI: 10.1007/BF00123377.

References

Baldessarini R, Cohen B, Teicher M . Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry. 1988; 45(1):79-91. DOI: 10.1001/archpsyc.1988.01800250095013. View

Johnson D . Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry. 1984; 45(5 Pt 2):13-21. View

Nambu K, Miyazaki H, Nakanishi Y, Matsunaga Y, Hashimoto M . Enzymatic hydrolysis of haloperidol decanoate and its inhibition by proteins. Biochem Pharmacol. 1987; 36(10):1715-22. DOI: 10.1016/0006-2952(87)90058-x. View

RIFKIN A, Quitkin F, Rabiner C, Klein D . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch Gen Psychiatry. 1977; 34(1):43-7. DOI: 10.1001/archpsyc.1977.01770130045004. View

Midha K, Hawes E, Hubbard J, McKay G, Rauw G, Sardessai M . Radioimmunoassay for fluphenazine sulfoxide in human plasma. J Pharmacol Methods. 1988; 19(1):63-74. DOI: 10.1016/0160-5402(88)90046-0. View

Curry S, DMello A, Mould G . Destruction of chlorpromazine during absorption in the rat in vivo and in vitro. Br J Pharmacol. 1971; 42(3):403-11. PMC: 1665658. DOI: 10.1111/j.1476-5381.1971.tb07125.x. View

De Buck R, Zelaschi N, Gilles C, Durdu J, Brauman H . Theoretical and practical importance of plasma levels of haloperidol. Correlations with clinical and computerized EEG data. Prog Neuropsychopharmacol. 1981; 5(5-6):499-502. DOI: 10.1016/0364-7722(81)90033-3. View

Hubbard J, Ganes D, Midha K . Prolonged pharmacologic activity of neuroleptic drugs. Arch Gen Psychiatry. 1987; 44(1):99-100. DOI: 10.1001/archpsyc.1987.01800130111024. View

Hogarty G, Schooler N, Ulrich R, Mussare F, Ferro P, Herron E . Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979; 36(12):1283-94. DOI: 10.1001/archpsyc.1979.01780120013001. View

10.

Jorgensen A . Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo. Eur J Clin Pharmacol. 1980; 18(4):355-60. DOI: 10.1007/BF00561395. View

11.

Gelders Y . Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate. Int Clin Psychopharmacol. 1986; 1 Suppl 1:1-11. View

12.

DEBERDT R, Elens P, Berghmans W, Heykants J, Woestenborghs R, Driesens F . Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiatr Scand. 1980; 62(4):356-63. DOI: 10.1111/j.1600-0447.1980.tb00621.x. View

13.

Marder S, Hawes E, Van Putten T, Hubbard J, McKay G, Mintz J . Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology (Berl). 1986; 88(4):480-3. DOI: 10.1007/BF00178510. View

14.

Ereshefsky L, Saklad S, Jann M, Davis C, Richards A, SEIDEL D . Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry. 1984; 45(5 Pt 2):50-9. View

15.

Schooler N, Levine J, Severe J, Brauzer B, DIMASCIO A, Klerman G . Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch Gen Psychiatry. 1980; 37(1):16-24. DOI: 10.1001/archpsyc.1980.01780140018002. View

16.

Yadalam K, Simpson G . Changing from oral to depot fluphenazine. J Clin Psychiatry. 1988; 49(9):346-8. View

17.

Curry S, Whelpton R, De Schepper P, Vranckx S, Schiff A . Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol. 1979; 7(4):325-31. PMC: 1429660. DOI: 10.1111/j.1365-2125.1979.tb00941.x. View

18.

Marder S, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G . Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry. 1984; 41(11):1025-9. DOI: 10.1001/archpsyc.1983.01790220015002. View

19.

de CUYPER H, Bollen J, van Praag H, Verstraeten D . Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. Br J Psychiatry. 1986; 148:560-6. DOI: 10.1192/bjp.148.5.560. View

20.

Dahl S . Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit. 1982; 4(1):33-40. DOI: 10.1097/00007691-198204000-00005. View